Denmark's Novo Nordisk, the world's largest insulin maker, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world's first once-weekly insulin injection. It is an ambitious and risky project, with research still at an early stage, but Chief Science Officer Mads Krogsgaard Thomsen thinks the super long-acting insulin, known as LAI287, could be a boon for people wanting to minimize use of needles.